Elutia closes SimpliDerm sale to Cellution Biologics, redirects focus to NXT-41x

Elutia Inc. announced on August 18, 2026 that it had completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc., a transaction first disclosed via an Asset Purchase Agreement executed July 16, 2026. The sale closed on August 17, 2026.

According to the 8-K's Item 2.01 disclosure, $7.7 million of the purchase price was paid to the Company at closing.¹ Elutia's press release described the deal in rounded terms, stating total consideration of up to $11 million, comprised of $8 million at closing, subject to customary adjustments for inventory levels and transaction expenses, plus additional contingent milestone payments of up to $3 million over the next 18 months.¹ The 8-K itself notes the purchase price is subject to possible adjustment based on the outcome of a post-closing inventory valuation and could include up to an additional $3 million in contingent payments potentially payable over the next eighteen months depending on the achievement of certain technology transfer and commercial milestones.¹

The SimpliDerm assets constituted substantially all of the assets of Elutia's Women's Health segment.¹ As part of closing, Elutia entered into a non-competition agreement covering human acellular dermis products for five years and a transition services agreement to provide post-closing support to Cellution Biologics for up to six months.¹ Elutia also amended its Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. to release the lien on the divested assets.¹

Elutia said the transaction sharpens its focus on NXT-41x, an antibiotic-eluting biomatrix intended for plastic and reconstructive surgery, where infection rates can run 15 to 20 percent, designed to reinforce soft tissue while locally delivering antibiotics to inhibit bacterial colonization.¹ The company said it expects FDA clearance of NXT-41x in the first half of 2027,¹ and believes it has secured sufficient funding to support operations through the first full year of the NXT-41x commercial launch in 2028.¹